APOA2 and cancer: Given our current understanding of neutrophil heterogeneity across multiple cancers, therapies that expand intratumoural MMP8+ and APOA2+ TANs whilst supressing IFIT1+, SPP1+ and CCL4+ TANs may be effective in improving immunotherapy responses in HCC (Figure 4).